News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The ASX biotech companies that lost puff on Pfizer vaccine news
Health & Biotech
Dr Boreham’s Crucible: Kazia reaches the ‘endgame’
Health & Biotech
Aussie biotechs join crusade for COVID-19 cure
Health & Biotech
Check up: COVID-19 is back in fashion
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech
Check up: Making it in America
Health & Biotech
COVID-19 treatments are a better bet than a vaccine
News
Rise and Shine: What you need to know before the ASX opens
News
Lunchtime ASX Small Cap Wrap: Oily to bed, oily to rise?
Health & Biotech
Noxopharm wants to test its anti-prostate cancer drug against COVID-19
Health & Biotech
Health: Noxopharm climbs 40pc after US FDA green lights trials of prostate drug
Health & Biotech
Health Kick Podcast: Skyrocketing prescription prices and Trump’s plan for the drug market
IPO Watch
IPO Watch: Noxopharm spin-off Nyrada gains 17.5pc on ASX debut
Health & Biotech
Health: Antisense’s anti-muscular dystrophy drug just took a big step
Health & Biotech
Health: Opthea’s taking its successful anti-AMD drug to a 1,320 patient phase III trial; raises $50m
News
